

Please see the coverage summary for Jan 2024 Codes as below:

Not covered experimental and investigational for MGB ACO, Commercial and ASO:

A4468	Exsufflation belt, includes all supplies and accessories
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm
A4541	Monthly supplies for use of device coded at e0733
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist
A9609	Fludeoxyglucose f18 up to 15 millicuries
C1600	Catheter, transluminal intravascular lesion preparation device, bladed, sheathed (insertable)
C1601	Endoscope, single-use (i.e., disposable), pulmonary, imaging/illumination device (insertable)
C1602	Orthopedic/device/drug matrix/absorbable bone void filler, antimicrobial-eluting (implantable)
C1603	Retrieval device, insertable, laser (used to retrieve intravascular inferior vena cava filter)
C1604	Graft, transmural transvenous arterial bypass (implantable), with all delivery system components
C7557	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed and intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention
C9793	3d predictive model generation for pre-planning of a cardiac procedure, using data from cardiac computed tomographic angiography with report
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply

E0530	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type
E0678	Non-pneumatic sequential compression garment, full leg
E0679	Non-pneumatic sequential compression garment, half leg
E0680	Non-pneumatic compression controller with sequential calibrated gradient pressure
E0681	Non-pneumatic compression controller without calibrated gradient pressure
E0682	Non-pneumatic sequential compression garment, full arm
E0732	Cranial electrotherapy stimulation (ces) system, any type
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist
E0735	Non-invasive vagus nerve stimulator
E3000	Speech volume modulation system, any type, including all components and accessories
J1413	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
J3401	Beremagene geperpavec-svdt for topical administration, containing nominal 5×10^9 pfu/ml vector genomes, per 0.1 ml
L5615	Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control
L5926	Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type
Q4279	Vendaje ac, per square centimeter

Q4287	Dermabind dl, per square centimeter
Q4288	Dermabind ch, per square centimeter
Q4289	Revoshield + amniotic barrier, per square centimeter
Q4290	Membrane wrap-hydro, per square centimeter
Q4291	Lamellas xt, per square centimeter
Q4292	Lamellas, per square centimeter
Q4293	Acesso dl, per square centimeter
Q4294	Amnio quad-core, per square centimeter
Q4295	Amnio tri-core amniotic, per square centimeter
Q4296	Rebound matrix, per square centimeter
Q4297	Emerge matrix, per square centimeter
Q4298	Amnicore pro, per square centimeter
Q4299	Amnicore pro+, per square centimeter
Q4300	Acesso tl, per square centimeter
Q4301	Activate matrix, per square centimeter
Q4302	Complete aca, per square centimeter

Q4303	Complete aa, per square centimeter
Q4304	Grafix plus, per square centimeter

Not covered experimental and investigational for Commercial and ASO only:

C9159	Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity
-------	--

Not covered benefit for ACO, Commercial and ASO:

A7023	Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical
C9160	Injection, daxibotulinumtoxina-lanm, 1 unit
E1301	Whirlpool tub, walk-in, portable
E2001	Suction pump, home model, portable or stationary, electric, any type, for use with external urine management system
G0019	Community health integration services performed by certified or trained auxiliary personnel, including a community health worker, under the direction of a physician or other practitioner, 60 minutes per calendar month, in the following activities to address social determinants of health (SDOH) need(s) that are significantly limiting the ability to diagnose or treat problem(s) addressed in an initiating visit:
G0022	Community health integration services, each additional 30 minutes per calendar month (list separately in addition to g0019)
G0023	Principal illness navigation services by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a patient navigator, 60 minutes per calendar month, in the following activities:
G0024	Principal illness navigation services, additional 30 minutes per calendar month (list separately in addition to g0023)
G0136	Administration of a standardized, evidence-based social determinants of health risk assessment tool, 5-15 minutes
G0140	Principal illness navigation-peer support by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a certified peer specialist, 60 minutes per calendar month, in the following activities:
G0146	Principal illness navigation - peer support, additional 30 minutes per calendar month (list separately in addition to g0140)
G9886	Behavioral counseling for diabetes prevention, in-person, group, 60 minutes

G9887	Behavioral counseling for diabetes prevention, distance learning, 60 minutes
G9888	Maintenance 5% wl from baseline weight in months 7-12

Not covered for Commercial and ASO, redirect to BH for MGB ACO:

G0137	Intensive outpatient services; weekly bundle, minimum of 9 services over a 7 contiguous day period, which can include:
-------	--

Covered when prior authorized for MGB ACO, Commercial and ASO:

C9794	Therapeutic radiology simulation-aided field setting; complex, including acquisition of pet and ct imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling)
C9795	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions
J0217	Injection, velmanase alfa-tycv, 1 mg
J1412	Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2×10^{13} vector genomes
J2508	Injection, pegunigalsidase alfa-iwxj, 1 mg

Covered when prior authorized for Commercial and ASO only:

A9608	Flotufolastat f 18, diagnostic, 1 millicurie
C9161	Injection, aflibercept hd, 1 mg
C9163	Injection, talquetamab-tgvs, 0.25 mg
C9165	Injection, elranatamab-bcmm, 1 mg
J1304	Injection, tofersen, 1 mg
J9321	Injection, epcoritamab-bysp, 0.16 mg
J9324	Injection, pemetrexed (pemrydi rtu), 10 mg
J9333	Injection, rozanolixizumab-noli, 1 mg
J9334	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc

Covered with no prior authorization required for MGB ACO, Commercial and ASO:

A4287	Disposable collection and storage bag for breast milk, any size, any type, each
-------	---

A4457	Enema tube, with or without adapter, any type, replacement only, each
A6520	Gradient compression garment, glove, padded, for nighttime use, each
A6521	Gradient compression garment, glove, padded, for nighttime use, custom, each
A6522	Gradient compression garment, arm, padded, for nighttime use, each
A6523	Gradient compression garment, arm, padded, for nighttime use, custom, each
A6524	Gradient compression garment, lower leg, and foot, padded, for nighttime use, each
A6525	Gradient compression garment, lower leg, and foot, padded, for nighttime use, custom, each
A6526	Gradient compression garment, full leg, and foot, padded, for nighttime use, each
A6527	Gradient compression garment, full leg, and foot, padded, for nighttime use, custom, each
A6528	Gradient compression garment, bra, for nighttime use, each
A6529	Gradient compression garment, bra, for nighttime use, custom, each
A6552	Gradient compression stocking, below knee, 30-40 mmhg, each
A6553	Gradient compression stocking, below knee, 30-40 mmhg, custom, each
A6554	Gradient compression stocking, below knee, 40 mmhg or greater, each

A6555	Gradient compression stocking, below knee, 40 mmhg or greater, custom, each
A6556	Gradient compression stocking, thigh length, 18-30 mmhg, custom, each
A6557	Gradient compression stocking, thigh length, 30-40 mmhg, custom, each
A6558	Gradient compression stocking, thigh length, 40 mmhg or greater, custom, each
A6559	Gradient compression stocking, full length/chap style, 18-30 mmhg, custom, each
A6560	Gradient compression stocking, full length/chap style, 30-40 mmhg, custom, each
A6561	Gradient compression stocking, full length/chap style, 40 mmhg or greater, custom, each
A6562	Gradient compression stocking, waist length, 18-30 mmhg, custom, each
A6563	Gradient compression stocking, waist length, 30-40 mmhg, custom, each
A6564	Gradient compression stocking, waist length, 40 mmhg or greater, custom, each
A6565	Gradient compression gauntlet, custom, each
A6566	Gradient compression garment, neck/head, each
A6567	Gradient compression garment, neck/head, custom, each
A6568	Gradient compression garment, torso, and shoulder, each

A6569	Gradient compression garment, torso/shoulder, custom, each
A6570	Gradient compression garment, genital region, each
A6571	Gradient compression garment, genital region, custom, each
A6572	Gradient compression garment, toe caps, each
A6573	Gradient compression garment, toe caps, custom, each
A6574	Gradient compression arm sleeve and glove combination, custom, each
A6575	Gradient compression arm sleeve and glove combination, each
A6576	Gradient compression arm sleeve, custom, medium weight, each
A6577	Gradient compression arm sleeve, custom, heavy weight, each
A6578	Gradient compression arm sleeve, each
A6579	Gradient compression glove, custom, medium weight, each
A6580	Gradient compression glove, custom, heavy weight, each
A6581	Gradient compression glove, each
A6582	Gradient compression gauntlet, each

A6583	Gradient compression wrap with adjustable straps, below knee, 30-50 mmhg, each
A6584	Gradient compression wrap with adjustable straps, not otherwise specified
A6585	Gradient pressure wrap with adjustable straps, above knee, each
A6586	Gradient pressure wrap with adjustable straps, full leg, each
A6587	Gradient pressure wrap with adjustable straps, foot, each
A6588	Gradient pressure wrap with adjustable straps, arm, each
A6589	Gradient pressure wrap with adjustable straps, bra, each
A6593	Accessory for gradient compression garment or wrap with adjustable straps, non-otherwise specified
A6594	Gradient compression bandaging supply, bandage liner, lower extremity, any size, or length, each
A6595	Gradient compression bandaging supply, bandage liner, upper extremity, any size, or length, each
A6596	Gradient compression bandaging supply, conforming gauze, per linear yard, any width, each
A6597	Gradient compression bandage roll, elastic long stretch, linear yard, any width, each
A6598	Gradient compression bandage roll, elastic medium stretch, per linear yard, any width, each
A6599	Gradient compression bandage roll, inelastic short stretch, per linear yard, any width, each
A6600	Gradient compression bandaging supply, high density foam sheet, per 250 square centimeters, each

A6601	Gradient compression bandaging supply, high density foam pad, any size or shape, each
A6602	Gradient compression bandaging supply, high density foam roll for bandage, per linear yard, any width, each
A6603	Gradient compression bandaging supply, low density channel foam sheet, per 250 square centimeters, each
A6604	Gradient compression bandaging supply, low density flat foam sheet, per 250 square centimeters, each
A6605	Gradient compression bandaging supply, padded foam, per linear yard, any width, each
A6606	Gradient compression bandaging supply, padded textile, per linear yard, any width, each
A6607	Gradient compression bandaging supply, tubular protective absorption layer, per linear yard, any width, each
A6608	Gradient compression bandaging supply, tubular protective absorption padded layer, per linear yard, any width, each
A6609	Gradient compression bandaging supply, not otherwise specified
A6610	Gradient compression stocking, below knee, 18-30 mmhg, custom, each
C7556	Bronchoscopy, rigid or flexible, with bronchial alveolar lavage and transendoscopic endobronchial ultrasound (ebus) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s), including fluoroscopic guidance, when performed
C7558	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed
C7560	Endoscopic retrograde cholangiopancreatography (ercp) with removal of foreign body(s) or stent(s) from biliary/pancreatic duct(s) and endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s)

G0011	Individual counseling for pre-exposure prophylaxis (prep) by physician or qualified health care professional (qhp) to prevent human immunodeficiency virus (hiv), includes hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence, 15-30 minutes
G0012	Injection of pre-exposure prophylaxis (prep) drug for hiv prevention, under skin or into muscle
G0013	Individual counseling for pre-exposure prophylaxis (prep) by clinical staff to prevent human immunodeficiency virus (hiv), includes: hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence
J0184	Injection, amisulpride, 1 mg
J0391	Injection, artesunate, 1 mg
J0576	Injection, buprenorphine extended-release (brixadi), 1 mg
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
J0873	Injection, daptomycin (xellia) not therapeutically equivalent to j0878, 1 mg
J1596	Injection, glycopyrrolate, 0.1 mg
J1939	Injection, bumetanide, 0.5 mg
J2404	Injection, nicardipine, 0.1 mg
J2679	Injection, fluphenazine hcl, 1.25 mg
J3425	Injection, hydroxocobalamin, 10 mcg
J9052	Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg

J9072	Injection, cyclophosphamide, (dr. reddy's), 5 mg
J9172	Injection, docetaxel (ingenus) not therapeutically equivalent to j9171, 1 mg
J9255	Injection, methotrexate (accord) not therapeutically equivalent to j9250 and j9260, 50 mg
J9258	Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg
L3161	Foot, adductus positioning device, adjustable

Covered with no prior authorization required for MGB ACO only:

C9159	Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity
J1105	Dexmedetomidine, oral, 1 mcg
J9324	Injection, pemetrexed (pemrydi rtu), 10 mg

Covered with no prior authorization required for Commercial and ASO only:

C9164	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
J9286	Injection, glofitamab-gxbm, 2.5 mg

Covered with no prior authorization required for MGB ACO, Commercial and ASO, redirect to BH when billed as BH:

G0017	Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); first 60 minutes
G0018	Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); each additional 30 minutes (list separately in addition to code for primary service)

Redirect to BH for MGB ACO, Commercial and ASO:

C7903	Group psychotherapy service for diagnosis, evaluation, or treatment of a mental health or substance use disorder provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service
-------	---

Redirect to Pharmacy for MGB ACO, Commercial and ASO:

J0402	Injection, aripiprazole (abilify asimtufii), 1 mg
J0751	Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
J0750	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
J2799	Injection, risperidone (uzedy), 1 mg
Q0516	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 30-days
Q0517	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 60-days
Q0518	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 90-days

Redirect to Pharmacy for Commercial and ASO only:

Q5132	Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
J1105	Dexmedetomidine, oral, 1 mcg

Reportable only, not reimbursable for MGB ACO, Commercial and ASO, Med Adv:

M1211	Most recent hemoglobin a1c level > 9.0%
M1212	Hemoglobin a1c level is missing, or was not performed during the measurement period (12 months)
M1213	No history of spirometry results with confirmed airflow obstruction (fev1/fvc < 70%) and present spirometry is >= 70%
M1214	Spirometry results with confirmed airflow obstruction (fev1/fvc < 70%) documented and reviewed
M1215	Documentation of medical reason(s) for not documenting and reviewing spirometry results (e.g., patients with dementia or tracheostomy)
M1216	No spirometry results with confirmed airflow obstruction (fev1/fvc < 70%) documented and/or no spirometry performed with results documented during the encounter
M1217	Documentation of system reason(s) for not documenting and reviewing spirometry results (e.g., spirometry equipment not available at the time of the encounter)
M1218	Patient has copd symptoms (e.g., dyspnea, cough/sputum, wheezing)
M1219	Anaphylaxis due to the vaccine on or before the date of the encounter

M1220	Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (ai) interpretation documented and reviewed; with evidence of retinopathy
M1221	Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (ai) interpretation documented and reviewed; without evidence of retinopathy
M1222	Glaucoma plan of care not documented, reason not otherwise specified
M1223	Glaucoma plan of care documented
M1224	Intraocular pressure (iop) reduced by a value less than 20% from the pre-intervention level
M1225	Intraocular pressure (iop) reduced by a value of greater than or equal to 20% from the pre-intervention level
M1226	Iop measurement not documented, reason not otherwise specified
M1227	Evidence-based therapy was prescribed
M1228	Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, has hcv treatment initiated within 3 months of the reactive hcv antibody test
M1229	Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, is referred within 1 month of the reactive hcv antibody test to a clinician who treats hcv infection
M1230	Patient has a reactive hcv antibody test and does not have a follow up hcv viral test, or patient has a reactive hcv antibody test and has a follow up hcv viral test that detects hcv viremia and is not referred to a clinician who treats hcv infection within 1 month and does not have hcv treatment initiated within 3 months of the reactive hcv antibody test, reason not given
M1231	Patient receives hcv antibody test with nonreactive result
M1232	Patient receives hcv antibody test with reactive result
M1233	Patient does not receive hcv antibody test or patient does receive hcv antibody test but results not documented, reason not given
M1234	Patient has a reactive hcv antibody test, and has a follow up hcv viral test that does not detect hcv viremia
M1235	Documentation or patient report of hcv antibody test or hcv rna test which occurred prior to the performance period
M1236	Baseline mrs > 2
M1237	Patient reason for not screening for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety (e.g., patient declined or other patient reasons)

M1238	Documentation that administration of second recombinant zoster vaccine could not occur during the performance period due to the recommended 2–6-month interval between doses (i.e., first dose received after October 31)
M1239	Patient did not respond to the question of patient felt heard and understood by this provider and team
M1240	Patient did not respond to the question of patient felt this provider and team put my best interests first when making recommendations about my care
M1241	Patient did not respond to the question of patient felt this provider and team saw me as a person, not just someone with a medical problem
M1242	Patient did not respond to the question of patient felt this provider and team understood what is important to me in my life
M1243	Patient provided a response other than "completely true" for the question of patient felt heard and understood by this provider and team
M1244	Patient provided a response other than "completely true" for the question of patient felt this provider and team put my best interests first when making recommendations about my care
M1245	Patient provided a response other than "completely true" for the question of patient felt this provider and team saw me as a person, not just someone with a medical problem
M1246	Patient provided a response other than "completely true" for the question of patient felt this provider and team understood what is important to me in my life
M1247	Patient responded "completely true" for the question of patient felt this provider and team put my best interests first when making recommendations about my care
M1248	Patient responded "completely true" for the question of patient felt this provider and team saw me as a person, not just someone with a medical problem
M1249	Patient responded "completely true" for the question of patient felt this provider and team understood what is important to me in my life
M1250	Patient responded as "completely true" for the question of patient felt heard and understood by this provider and team
M1251	Patients for whom a proxy completed the entire hu survey on their behalf for any reason (no patient involvement)
M1252	Patients who did not complete at least one of the four patient experience hu survey items and return the hu survey within 60 days of the ambulatory palliative care visit
M1253	Patients who respond on the patient experience hu survey that they did not receive care by the listed ambulatory palliative care provider in the last 60 days (disavowal)

M1254	Patients who were deceased when the hu survey reached them
M1255	Patients who have another reason for visiting the clinic [not prenatal or postpartum care] and have a positive pregnancy test but have not established the clinic as an ob provider (e.g., plan to terminate the pregnancy or seek prenatal services elsewhere)
M1256	Prior history of known cvd
M1257	Cvd risk assessment not performed or incomplete (e.g., cvd risk assessment was not documented), reason not otherwise specified
M1258	Cvd risk assessment performed, have a documented calculated risk score
M1259	Patients listed on the kidney-pancreas transplant waitlist or who received a living donor transplant within the first year following initiation of dialysis
M1260	Patients who were not listed on the kidney-pancreas transplant waitlist or patients who did not receive a living donor transplant within the first year following initiation of dialysis
M1261	Patients that were on the kidney or kidney-pancreas waitlist prior to initiation of dialysis
M1262	Patients who had a transplant prior to initiation of dialysis
M1263	Patients in hospice on their initiation of dialysis date or during the month of evaluation
M1264	Patients age 75 or older on their initiation of dialysis date
M1265	CMS medical evidence form 2728 for dialysis patients: initial form completed
M1266	Patients admitted to a skilled nursing facility (SNF)
M1267	Patients not on any kidney or kidney-pancreas transplant waitlist or is not in active status on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period
M1268	Patients on active status on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period
M1269	Receiving esrd mcp dialysis services by the provider on the last day of the reporting month
M1270	Patients not on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period
M1271	Patients with dementia at any time prior to or during the month

M1272	Patients on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period
M1273	Patients who were admitted to a skilled nursing facility (SNF) within one year of dialysis initiation according to the CMS-2728 form
M1274	Patients who were admitted to a skilled nursing facility (SNF) during the month of evaluation were excluded from that month
M1275	Patients determined to be in hospice were excluded from month of evaluation and the remainder of reporting period
M1276	Bmi documented outside normal parameters, no follow-up plan documented, no reason given
M1277	Colorectal cancer screening results documented and reviewed
M1278	Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented
M1279	Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given
M1280	Women who had a bilateral mastectomy or who have a history of a bilateral mastectomy or for whom there is evidence of a right and a left unilateral mastectomy
M1281	Blood pressure reading not documented, reason not given
M1282	Patient screened for tobacco use and identified as a tobacco non-user
M1283	Patient screened for tobacco use and identified as a tobacco user
M1284	Patients age 66 or older in institutional special needs plans (snp) or residing in long term care with pos code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period
M1285	Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified
M1286	Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason
M1287	Bmi is documented below normal parameters and a follow-up plan is documented
M1288	Documented reason for not screening or recommending a follow-up for high blood pressure

M1289	Patient identified as tobacco user did not receive tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy)
M1290	Patient not eligible due to active diagnosis of hypertension
M1291	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period
M1292	Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period
M1293	Bmi is documented above normal parameters and a follow-up plan is documented
M1294	Normal blood pressure reading documented, follow-up not required
M1295	Patients with a diagnosis or past history of total colectomy or colorectal cancer
M1296	Bmi is documented within normal parameters and no follow-up plan is required
M1297	Bmi not documented due to medical reason or patient refusal of height or weight measurement
M1298	Documentation of patient pregnancy anytime during the measurement period prior to and including the current encounter
M1299	Influenza immunization administered or previously received
M1300	Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons)
M1301	Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy)

M1302	Screening, diagnostic, film digital or digital breast tomosynthesis (3d) mammography results documented and reviewed
M1303	Hospice services provided to patient any time during the measurement period
M1304	Patient did not receive any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
M1305	Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
M1306	Patient had anaphylaxis due to the pneumococcal vaccine any time during or before the measurement period
M1307	Documentation stating the patient has received or is currently receiving palliative or hospice care
M1308	Influenza immunization was not administered, reason not given
M1309	Palliative care services provided to patient any time during the measurement period
M1310	Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user
M1311	Anaphylaxis due to the vaccine on or before the date of the encounter
M1312	Patient not screened for tobacco use
M1313	Tobacco screening not performed or tobacco cessation intervention not provided during the measurement period or in the six months prior to the measurement period
M1314	Bmi not documented and no reason is given
M1315	Colorectal cancer screening results were not documented and reviewed; reason not otherwise specified

M1316	Current tobacco non-user
M1317	Patients who are counseled on connection with a csp and explicitly opt out
M1318	Patients who did not have documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening or documentation that there was no contact with a csp
M1319	Patients who had documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening
M1320	Patients who screened positive for at least 1 of the 5 hrsns
M1321	Patients who were not seen within 7 weeks following the date of injection for follow up or who did not have a documented iop or no plan of care documented if the iop was >25 mm hg
M1322	Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop \leq 25 mm hg for injected eye
M1323	Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop >25 mm hg and a plan of care was documented
M1324	Patients who had an intravitreal or periocular corticosteroid injection (e.g., triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant, or fluocinolone intravitreal implant)
M1325	Patients who were not seen for reasons documented by clinician for patient or medical reasons (e.g., inadequate time for follow-up, patients who received a prior intravitreal or periocular steroid injection within the last six (6) months and had a subsequent iop evaluation with iop <25mm hg within seven (7) weeks of treatment)
M1326	Patients with a diagnosis of hypotony
M1327	Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 8 weeks
M1328	Patients with a diagnosis of acute vitreous hemorrhage

M1329	Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 8 weeks after initial acute pvd encounter
M1330	Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up)
M1331	Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 8 weeks from initial exam
M1332	Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 2 weeks
M1333	Acute vitreous hemorrhage
M1334	Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 2 weeks after initial acute pvd encounter
M1335	Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up)
M1336	Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 2 weeks
M1337	Acute pvd
M1338	Patients who had follow-up assessment 30 to 180 days after the index assessment who did not demonstrate positive improvement or maintenance of functioning scores during the performance period
M1339	Patients who had follow-up assessment 30 to 180 days after the index assessment who demonstrated positive improvement or maintenance of functioning scores during the performance period
M1340	Index assessment completed using the 12-item whodas 2.0 or sds during the denominator identification period
M1341	Patients who did not have a follow-up assessment or did not have an assessment within 30 to 180 days after the index assessment during the performance period
M1342	Patients who died during the performance period

M1343	Patients who are at pam level 4 at baseline or patients who are flagged with extreme straight line response sets on the pam
M1344	Patients who did not have a baseline pam score and/or a second score within 6 to 12 month of baseline pam score
M1345	Patients who had a baseline pam score and a second score within 6 to 12 month of baseline pam score
M1346	Patients who did not have a net increase in pam score of at least 6 points within a 6 to 12 month period
M1347	Patients who achieved a net increase in pam score of at least 3 points in a 6 to 12 month period (passing)
M1348	Patients who achieved a net increase in pam score of at least 6-points in a 6 to 12 month period (excellent)
M1349	Patients who did not have a net increase in pam score of at least 3 points within 6 to 12 month period
M1350	Patients who had a completed suicide safety plan initiated, reviewed, or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter
M1351	Patients who had a suicide safety plan initiated, reviewed, or updated and reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation
M1352	Suicidal ideation and/or behavior symptoms based on the c-ssrs or equivalent assessment
M1353	Patients who did not have a completed suicide safety plan initiated, reviewed, or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter
M1354	Patients who did not have a suicide safety plan initiated, reviewed, or updated or reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation
M1355	Suicide risk based on their clinician's evaluation or a clinician-rated tool
M1356	Patients who died during the measurement period

M1357	Patients who had a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment
M1358	Patients who did not have a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment
M1359	Index assessment during the denominator period when the suicidal ideation and/or behavior symptoms or increased suicide risk by clinician determination occurs and a non-zero c-ssrs score is obtained
M1360	Suicidal ideation and/or behavior symptoms based on the c-ssrs
M1361	Suicide risk based on their clinician's evaluation or a clinician-rated tool
M1362	Patients who died during the measurement period
M1363	Patients who did not have a follow-up assessment within 120 days of the index assessment
M1364	Calculated 10-year ascvd risk score of = 20 percent during the performance period
M1365	Patient encounter during the performance period with hospice and palliative care specialty code 17
M1366	Focusing on women's health mips value pathway
M1367	Quality care for the treatment of ear, nose, and throat disorders mips value pathway
M1368	Prevention and treatment of infectious disorders including hepatitis c and hiv mips value pathway
M1369	Quality care in mental health and substance use disorders mips value pathway
M1370	Rehabilitative support for musculoskeletal care mips value pathway

New to Market not covered unless prior authorized for MGB ACO, Commercial and ASO:

C9162	Injection, avacincaptad pegol, 0.1 mg
-------	---------------------------------------

New to Market not covered unless prior authorized for MGB ACO only:

C9161	Injection, aflibercept hd, 1 mg
C9163	Injection, talquetamab-tgvs, 0.25 mg
C9164	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
C9165	Injection, elranatamab-bcmm, 1 mg
J1304	Injection, tofersen, 1 mg
J9321	Injection, epcoritamab-bysp, 0.16 mg
J9286	Injection, glofitamab-gxbm, 2.5 mg
J9333	Injection, rozanolixizumab-noli, 1 mg
J9334	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
Q5132	Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg

Coverage is determined by NDC (11-digit National Drug Code) billed for MGB ACO, Commercial and ASO:

J0799	FDA approved prescription drug, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv), not otherwise classified
-------	--

CPT codes not covered for Med Advantage:

90589	Chikungunya virus vaccine, live attenuated, for intramuscular use
90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use
90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use
97037	Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non-ablative) for post-operative pain reduction

CPT codes covered when prior authorized via eviCore for Med Adv:

81457	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability
-------	--

81458	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability
81459	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements
81462	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements
81463	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability
81464	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements

CPT codes covered when prior authorized for Med Adv:

22836	Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; up to 7 vertebral segments
22837	Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; 8 or more vertebral segments
22838	Revision (eg, augmentation, division of tether), replacement, or removal of thoracic vertebral body tethering, including thoracoscopy, when performed
27278	Arthrodesis, sacroiliac joint, percutaneous, with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device
31242	Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve
31243	Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve
33276	Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed
33277	Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)
33278	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)
33279	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only

33280	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only
33281	Repositioning of phrenic nerve stimulator transvenous lead(s)
33287	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator
33288	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)
52284	Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed
58580	Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency
61889	Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including craniectomy or craniotomy, when performed, with direct or inductive coupling, with connection to depth and/or cortical strip electrode array(s)
61891	Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s)
61892	Removal of skull-mounted cranial neurostimulator pulse generator or receiver with cranioplasty, when performed
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array
64597	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)
64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator
81517	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years
92972	Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)
93150	Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming

93151	Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system
93152	Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography
93153	Interrogation without programming of implanted phrenic nerve stimulator system

CPT codes covered with no prior authorization required for Med Adv:

67516	Suprachoroidal space injection of pharmacologic agent (separate procedure)
75580	Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional
76984	Ultrasound, intraoperative thoracic aorta (eg, epiaortic), diagnostic
76987	Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; including placement and manipulation of transducer, image acquisition, interpretation, and report
76988	Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; placement, manipulation of transducer, and image acquisition only
76989	Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; interpretation and report only
82166	Anti-mullerian hormone (AMH)
86041	Acetylcholine receptor (AChR); binding antibody
86042	Acetylcholine receptor (AChR); blocking antibody
86043	Acetylcholine receptor (AChR); modulating antibody
86366	Muscle-specific kinase (MuSK) antibody
87523	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription, when performed
92622	Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; first 60 minutes

92623	Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; each additional 15 minutes (List separately in addition to code for primary procedure)
93584	Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; anomalous or persistent superior vena cava when it exists as a second contralateral superior vena cava, with native drainage to heart (List separately in addition to code for primary procedure)
93585	Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; azygos/hemiazygos venous system (List separately in addition to code for primary procedure)
93586	Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; coronary sinus (List separately in addition to code for primary procedure)
93587	Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating at or above the heart (eg, from innominate vein) (List separately in addition to code for primary procedure)
93588	Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating below the heart (eg, from the inferior vena cava) (List separately in addition to code for primary procedure)
96547	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; first 60 minutes (List separately in addition to code for primary procedure)
96548	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; each additional 30 minutes (List separately in addition to code for primary procedure)
97550	Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face; initial 30 minutes
97551	Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face; each additional 15 minutes (List separately in addition to code for primary service)
97552	Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face with multiple sets of caregivers
99459	Pelvic examination (List separately in addition to code for primary procedure)

HCPSC codes not covered for Med Adv:

A4457	Enema tube, with or without adapter, any type, replacement only, each
A4468	Exsufflation belt, includes all supplies and accessories
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm
A7023	Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply
E1301	Whirlpool tub, walk-in, portable
J1105	Dexmedetomidine, oral, 1 mcg

HCPSC codes covered when prior authorized for Med Adv:

A4541	Monthly supplies for use of device coded at e0733
A9608	Flotufolastat f 18, diagnostic, 1 millicurie
A9609	Fludeoxyglucose f18 up to 15 millicuries
C1600	Catheter, transluminal intravascular lesion preparation device, bladed, sheathed (insertable)
C1601	Endoscope, single-use (i.e., disposable), pulmonary, imaging/illumination device (insertable)
C1602	Orthopedic/device/drug matrix/absorbable bone void filler, antimicrobial-eluting (implantable)
C1603	Retrieval device, insertable, laser (used to retrieve intravascular inferior vena cava filter)
C7557	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed and intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention
C9160	Injection, daxibotulinumtoxina-lanm, 1 unit
C9161	Injection, aflibercept hd, 1 mg
C9162	Injection, avacincaptad pegol, 0.1 mg
C9163	Injection, talquetamab-tgvs, 0.25 mg
C9165	Injection, elranatamab-bcmm, 1 mg

C9793	3d predictive model generation for pre-planning of a cardiac procedure, using data from cardiac computed tomographic angiography with report
C9794	Therapeutic radiology simulation-aided field setting; complex, including acquisition of pet and ct imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling)
C9795	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions
E0680	Non-pneumatic compression controller with sequential calibrated gradient pressure
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
E0735	Non-invasive vagus nerve stimulator
J0217	Injection, velmanase alfa-tycv, 1 mg
J0576	Injection, buprenorphine extended-release (brixadi), 1 mg
J1304	Injection, tofersen, 1 mg
J1412	Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2×10^{13} vector genomes
J1413	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
J2508	Injection, pegunigalsidase alfa-iwxj, 1 mg
J3401	Beremagene geperpavec-svdt for topical administration, containing nominal 5×10^9 pfu/ml vector genomes, per 0.1 ml
J9286	Injection, glofitamab-gxbm, 2.5 mg
J9321	Injection, epcoritamab-bysp, 0.16 mg
J9333	Injection, rozanolixizumab-noli, 1 mg
J9334	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
L5615	Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control
L5926	Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type

HCPSC codes covered with no prior authorization required for Med Adv:

A4287	Disposable collection and storage bag for breast milk, any size, any type, each
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist
A6520	Gradient compression garment, glove, padded, for nighttime use, each
A6521	Gradient compression garment, glove, padded, for nighttime use, custom, each
A6522	Gradient compression garment, arm, padded, for nighttime use, each
A6523	Gradient compression garment, arm, padded, for nighttime use, custom, each
A6524	Gradient compression garment, lower leg, and foot, padded, for nighttime use, each
A6525	Gradient compression garment, lower leg, and foot, padded, for nighttime use, custom, each
A6526	Gradient compression garment, full leg, and foot, padded, for nighttime use, each
A6527	Gradient compression garment, full leg, and foot, padded, for nighttime use, custom, each
A6528	Gradient compression garment, bra, for nighttime use, each
A6529	Gradient compression garment, bra, for nighttime use, custom, each
A6552	Gradient compression stocking, below knee, 30-40 mmhg, each
A6553	Gradient compression stocking, below knee, 30-40 mmhg, custom, each
A6554	Gradient compression stocking, below knee, 40 mmhg or greater, each
A6555	Gradient compression stocking, below knee, 40 mmhg or greater, custom, each
A6556	Gradient compression stocking, thigh length, 18-30 mmhg, custom, each
A6557	Gradient compression stocking, thigh length, 30-40 mmhg, custom, each
A6558	Gradient compression stocking, thigh length, 40 mmhg or greater, custom, each
A6559	Gradient compression stocking, full length/chap style, 18-30 mmhg, custom, each
A6560	Gradient compression stocking, full length/chap style, 30-40 mmhg, custom, each

A6561	Gradient compression stocking, full length/chap style, 40 mmhg or greater, custom, each
A6562	Gradient compression stocking, waist length, 18-30 mmhg, custom, each
A6563	Gradient compression stocking, waist length, 30-40 mmhg, custom, each
A6564	Gradient compression stocking, waist length, 40 mmhg or greater, custom, each
A6565	Gradient compression gauntlet, custom, each
A6566	Gradient compression garment, neck/head, each
A6567	Gradient compression garment, neck/head, custom, each
A6568	Gradient compression garment, torso, and shoulder, each
A6569	Gradient compression garment, torso/shoulder, custom, each
A6570	Gradient compression garment, genital region, each
A6571	Gradient compression garment, genital region, custom, each
A6572	Gradient compression garment, toe caps, each
A6573	Gradient compression garment, toe caps, custom, each
A6574	Gradient compression arm sleeve and glove combination, custom, each
A6575	Gradient compression arm sleeve and glove combination, each
A6576	Gradient compression arm sleeve, custom, medium weight, each
A6577	Gradient compression arm sleeve, custom, heavy weight, each
A6578	Gradient compression arm sleeve, each
A6579	Gradient compression glove, custom, medium weight, each
A6580	Gradient compression glove, custom, heavy weight, each
A6581	Gradient compression glove, each
A6582	Gradient compression gauntlet, each

A6583	Gradient compression wrap with adjustable straps, below knee, 30-50 mmhg, each
A6584	Gradient compression wrap with adjustable straps, not otherwise specified
A6585	Gradient pressure wrap with adjustable straps, above knee, each
A6586	Gradient pressure wrap with adjustable straps, full leg, each
A6587	Gradient pressure wrap with adjustable straps, foot, each
A6588	Gradient pressure wrap with adjustable straps, arm, each
A6589	Gradient pressure wrap with adjustable straps, bra, each
A6593	Accessory for gradient compression garment or wrap with adjustable straps, non-otherwise specified
A6594	Gradient compression bandaging supply, bandage liner, lower extremity, any size, or length, each
A6595	Gradient compression bandaging supply, bandage liner, upper extremity, any size, or length, each
A6596	Gradient compression bandaging supply, conforming gauze, per linear yard, any width, each
A6597	Gradient compression bandage roll, elastic long stretch, linear yard, any width, each
A6598	Gradient compression bandage roll, elastic medium stretch, per linear yard, any width, each
A6599	Gradient compression bandage roll, inelastic short stretch, per linear yard, any width, each
A6600	Gradient compression bandaging supply, high density foam sheet, per 250 square centimeters, each
A6601	Gradient compression bandaging supply, high density foam pad, any size or shape, each
A6602	Gradient compression bandaging supply, high density foam roll for bandage, per linear yard, any width, each
A6603	Gradient compression bandaging supply, low density channel foam sheet, per 250 square centimeters, each
A6604	Gradient compression bandaging supply, low density flat foam sheet, per 250 square centimeters, each
A6605	Gradient compression bandaging supply, padded foam, per linear yard, any width, each
A6606	Gradient compression bandaging supply, padded textile, per linear yard, any width, each
A6607	Gradient compression bandaging supply, tubular protective absorption layer, per linear yard, any width, each

A6608	Gradient compression bandaging supply, tubular protective absorption padded layer, per linear yard, any width, each
A6609	Gradient compression bandaging supply, not otherwise specified
A6610	Gradient compression stocking, below knee, 18-30 mmhg, custom, each
C1604	Graft, transmural transvenous arterial bypass (implantable), with all delivery system components
C7556	Bronchoscopy, rigid or flexible, with bronchial alveolar lavage and transendoscopic endobronchial ultrasound (ebus) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s), including fluoroscopic guidance, when performed
C7558	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed
C7560	Endoscopic retrograde cholangiopancreatography (ercp) with removal of foreign body(s) or stent(s) from biliary/pancreatic duct(s) and endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s)
C9159	Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity
C9164	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
E0530	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type
E0678	Non-pneumatic sequential compression garment, full leg
E0679	Non-pneumatic sequential compression garment, half leg
E0681	Non-pneumatic compression controller without calibrated gradient pressure
E0682	Non-pneumatic sequential compression garment, full arm
E0732	Cranial electrotherapy stimulation (ces) system, any type
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist
E2001	Suction pump, home model, portable or stationary, electric, any type, for use with external urine management system
E3000	Speech volume modulation system, any type, including all components and accessories
G0011	Individual counseling for pre-exposure prophylaxis (prep) by physician or qualified health care professional (qhp) to prevent human immunodeficiency virus (hiv), includes hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence, 15-30 minutes
G0012	Injection of pre-exposure prophylaxis (prep) drug for hiv prevention, under skin or into muscle

G0013	Individual counseling for pre-exposure prophylaxis (prep) by clinical staff to prevent human immunodeficiency virus (hiv), includes: hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence
G0019	Community health integration services performed by certified or trained auxiliary personnel, including a community health worker, under the direction of a physician or other practitioner, 60 minutes per calendar month, in the following activities to address social determinants of health (SDOH) need(s) that are significantly limiting the ability to diagnose or treat problem(s) addressed in an initiating visit:
G0022	Community health integration services, each additional 30 minutes per calendar month (list separately in addition to g0019)
G9886	Behavioral counseling for diabetes prevention, in-person, group, 60 minutes
G9887	Behavioral counseling for diabetes prevention, distance learning, 60 minutes
G9888	Maintenance 5% wl from baseline weight in months 7-12
J0184	Injection, amisulpride, 1 mg
J0391	Injection, artesunate, 1 mg
J0402	Injection, aripiprazole (abilify asimtufii), 1 mg
J0751	Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
J0750	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
J0799	Fda approved prescription drug, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv), not otherwise classified
J0873	Injection, daptomycin (xellia) not therapeutically equivalent to j0878, 1 mg
J1596	Injection, glycopyrrolate, 0.1 mg
J1939	Injection, bumetanide, 0.5 mg
J2404	Injection, nicardipine, 0.1 mg
J2679	Injection, fluphenazine hcl, 1.25 mg
J2799	Injection, risperidone (uzedy), 1 mg

J3425	Injection, hydroxocobalamin, 10 mcg
J9052	Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg
J9072	Injection, cyclophosphamide, (dr. reddy's), 5 mg
J9172	Injection, docetaxel (ingenus) not therapeutically equivalent to j9171, 1 mg
J9255	Injection, methotrexate (accord) not therapeutically equivalent to j9250 and j9260, 50 mg
J9258	Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg
J9324	Injection, pemetrexed (pemrydi rtu), 10 mg
L3161	Foot, adductus positioning device, adjustable
Q0516	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 30-days
Q0517	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 60-days
Q0518	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 90-days
Q4279	Vendaje ac, per square centimeter
Q4287	Dermabind dl, per square centimeter
Q4288	Dermabind ch, per square centimeter
Q4289	Revoshield + amniotic barrier, per square centimeter
Q4290	Membrane wrap-hydro, per square centimeter
Q4291	Lamellas xt, per square centimeter
Q4292	Lamellas, per square centimeter
Q4293	Acesso dl, per square centimeter
Q4294	Amnio quad-core, per square centimeter
Q4295	Amnio tri-core amniotic, per square centimeter
Q4296	Rebound matrix, per square centimeter
Q4297	Emerge matrix, per square centimeter
Q4298	Amnicore pro, per square centimeter
Q4299	Amnicore pro+, per square centimeter
Q4300	Acesso tl, per square centimeter
Q4301	Activate matrix, per square centimeter
Q4302	Complete aca, per square centimeter
Q4303	Complete aa, per square centimeter
Q4304	Grafix plus, per square centimeter
Q5132	Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg

HCPSC codes no prior authorization required when billed as medical, redirect to BH when billed as BH for Adv Med:

G0023	Principal illness navigation services by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a patient navigator, 60 minutes per calendar month, in the following activities:
G0024	Principal illness navigation services, additional 30 minutes per calendar month (list separately in addition to g0023)
G0136	Administration of a standardized, evidence-based social determinants of health risk assessment tool, 5-15 minutes
G0140	Principal illness navigation-peer support by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a certified peer specialist, 60 minutes per calendar month, in the following activities:
G0146	Principal illness navigation - peer support, additional 30 minutes per calendar month (list separately in addition to g0140)

HCPSC codes redirect to BH for Med Adv:

C7903	Group psychotherapy service for diagnosis, evaluation, or treatment of a mental health or substance use disorder provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service
G0017	Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); first 60 minutes
G0018	Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); each additional 30 minutes (list separately in addition to code for primary service)

G0137	<p>Intensive outpatient services; weekly bundle, minimum of 9 services over a 7 contiguous day period, which can include individual and group therapy with physicians or psychologists (or other mental health professionals to the extent authorized under state law); occupational therapy requiring the skills of a qualified occupational therapist; services of social workers, trained psychiatric nurses, and other staff trained to work with psychiatric patients; individualized activity therapies that are not primarily recreational or diversionary; family counseling (the primary purpose of which is treatment of the individual's condition); patient training and education (to the extent that training and educational activities are closely and clearly related to individual's care and treatment); diagnostic services; and such other items and services (excluding meals and transportation) that are reasonable and necessary for the diagnosis or active treatment of the individual's condition, reasonably expected to improve or maintain the individual's condition and functional level and to prevent relapse or hospitalization, and furnished pursuant to such guidelines relating to frequency and duration of services in accordance with a physician certification and plan of treatment (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure</p>
-------	---